Colinz Laboratories Limited (BOM:531210)

India flag India · Delayed Price · Currency is INR
48.04
-1.66 (-3.34%)
At close: Jan 22, 2026
-11.85%
Market Cap121.02M
Revenue (ttm)58.72M
Net Income (ttm)4.63M
Shares Out2.52M
EPS (ttm)1.84
PE Ratio26.11
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume693
Average Volume1,377
Open48.10
Previous Close49.70
Day's Range48.00 - 50.00
52-Week Range36.11 - 88.70
Beta-0.32
RSI47.32
Earnings DateJan 24, 2026

About Colinz Laboratories

Colinz Laboratories Limited manufactures, markets, and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin,... [Read more]

Industry Pharmaceutical Preparations
Founded 1986
Employees 65
Stock Exchange Bombay Stock Exchange
Ticker Symbol 531210
Full Company Profile

Financial Performance

In 2024, Colinz Laboratories's revenue was 65.28 million, a decrease of -7.14% compared to the previous year's 70.30 million. Earnings were 4.97 million, an increase of 2.03%.

Financial Statements